STOCKHOLM, June 20, 2019 /PRNewswire/ -- OxThera AB, a biopharmaceutical company dedicated to improve the lives of people living with Primary Hyperoxaluria, today announced that the first patients in a Phase 3 study of Oxabact ® have completed the study and transitioned to an open-label extension part.
The shareholders in OxThera AB (publ), 556681-5667, are hereby given notice to attend. Extraordinary General Meeting (”EGM”) on 3rd March,
In patients, mostly children, this life-threatening disease accumulates oxalate in the body and the oxalate forms insoluble crystals and stones in different organs (kidney, liver, heart and eyes). There is no treatment for primary hyperoxaluria and the patients enter end-stage-renal dialysis within a few years. Primary hyperoxaluria is a rare autosomal recessive inherited disorder of glyoxylate metabolism that causes an endogenous overproduction of oxalate. Oxalate cannot be degraded in humans and is mostly eliminated by the kidneys. The oxalate overproduction leads to kidney stones, nephrocalcinosis and kidney damage.
OxThera AB (Stockholm, Sweden) is a biopharmaceutical company developing an inovative novel therapy for Primary Hyperoxaluria. OxThera’s pipeline is built around a bacterial strain isolated from the human gut, Oxabact®, which exclusively uses oxalate as an energy source. STOCKHOLM, July 10, 2018 /PRNewswire/ -- OxThera AB, a Stockholm-based privately-held biopharmaceutical company, today announced that the Phase 3 study with Oxabact(R) in Primary Hyperoxaluria (PH) is now fully open for recruitment. OxThera currently has two products in its pipeline: Oxabact ® for the treatment of primary hyperoxaluria, and Oxazyme ®, an oxalate decarboxylase, for the treatment of oxalate malabsorption and OxThera AB, a Stockholm-based privately-held biopharmaceutical company, today announced that the Phase 3 study with Oxabact ® in Primary Hyperoxaluria (PH) is now fully open for recruitment.
OxThera AB (Stockholm, Sweden) is a biopharmaceutical company developing an inovative novel therapy for Primary Hyperoxaluria. OxThera’s pipeline is built around a bacterial strain isolated from the human gut, Oxabact®, which exclusively uses oxalate as an energy source.
Health-Related Quality of Life (HRQoL) in Primary Hyperoxaluria (PH). Frank Modersitzki Novome Biotechnologies, Oxthera AB, PHOx Therapeutics,. 4:45 pm OxThera. OxThera is a biopharmaceutical company with products in late stage clinical development focusing on Primary and Secondary Hyperoxaluria.
formigenes designed to target the orphan disease Primary Hyperoxaluria. is developed byprivately-held Swedish biopharmaceutical company OxThera.
OxThera AB, a Stockholm-based privately-held biopharmaceutical company, today announced that it has initiated a clinical study in in Primary Hyperoxaluria. This announcement bolsters the Company’s position as a leader in developing therapies for hyperoxaluria, a debilitating condition that, if untreated, leads to kidney damage and end-stage renal disease. Mission: Stockholm-based Oxthera is currently advancing two late-stage clinical products for the treatment of primary and secondary hyperoxaluria, a kidney disease that is caused by the build-up of oxalate in plasma and urine.Primary hyperoxaluria is a rare genetic disorder that affects primarily children causing progressive kidney damage, calcification of the kidneys, and finally kidney failure.
All clinics participating in the study are approved by Competent authorities in Europe and US and are initiating patient screening.
Fk kassan
OxThera currently has two products in its pipeline: Oxabact ® for the treatment of primary hyperoxaluria, and Oxazyme ®, an oxalate decarboxylase, for the treatment of oxalate malabsorption and OxThera AB, a Stockholm-based privately-held biopharmaceutical company, today announced that the Phase 3 study with Oxabact ® in Primary Hyperoxaluria (PH) is now fully open for recruitment. All clinics participating in the study are approved by Competent authorities in Europe and US and are initiating patient screening .
Oxabact planeras nu att användas för behandling av den sällsynta sjukdomen korttarmssyndrom (Short Bowel Syndrome, SBS). Det är en
Forskningsbolaget får en kapitalinjektion till den fortsatta utvecklingen av Oxabact, mot den sällsynta sjukdomen primär hyperoxaluri. Primary hyperoxaluria (PH) is a rare genetic metabolic disorder.
Pekka coc
se lagfarter
jobb dagmamma
ad assistent jobb
skriva intyg till anställd exempel
Background: Primary hyperoxaluria (PH) is a rare, genetic disorder which involves the overproduction of endogenous oxalate, leading to hyperoxaluria, recurrent urolithiasis and/or progressive nephrocalcinosis and eventually resulting in kidney failure and systemic oxalosis.
ePHex - An OxThera Clinical Trial in Primary Hyperoxaluria, Stockholm, Sweden.